Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Common Equity (2016 - 2025)

Karyopharm Therapeutics' Common Equity history spans 14 years, with the latest figure at -$292.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 57.47% year-over-year to -$292.9 million; the TTM value through Dec 2025 reached -$292.9 million, down 57.47%, while the annual FY2025 figure was -$292.9 million, 57.47% down from the prior year.
  • Common Equity reached -$292.9 million in Q4 2025 per KPTI's latest filing, down from -$269.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$16.7 million in Q4 2022 to a low of -$292.9 million in Q4 2025.
  • Average Common Equity over 5 years is -$134.6 million, with a median of -$129.1 million recorded in 2021.
  • Peak YoY movement for Common Equity: soared 79.09% in 2022, then plummeted 717.76% in 2023.
  • A 5-year view of Common Equity shows it stood at -$79.7 million in 2021, then skyrocketed by 79.09% to -$16.7 million in 2022, then crashed by 717.76% to -$136.2 million in 2023, then plummeted by 36.57% to -$186.0 million in 2024, then plummeted by 57.47% to -$292.9 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Common Equity are -$292.9 million (Q4 2025), -$269.3 million (Q3 2025), and -$238.9 million (Q2 2025).